key: cord-0930167-fs050m3r
authors: McConachie, D.; McConachie, N.; White, P.; Crossley, R.; Izzath, W.
title: Mechanical thrombectomy for acute ischaemic stroke during the COVID-19 pandemic: changes to UK practice and lessons learned
date: 2020-07-10
journal: Clin Radiol
DOI: 10.1016/j.crad.2020.07.001
sha: e4c6684d23be7367ed6ff288f796801ce0430699
doc_id: 930167
cord_uid: fs050m3r

Abstract Aim To describe evolving practices in the provision of mechanical thrombectomy (MT) services across the UK during the COVID-19 pandemic, the responses of and impact on MT teams, and the effects on training. Materials and methods The UK Neurointerventional Group (UKNG) and the British Society of Neuroradiologists (BSNR) sent out a national survey on 1 May 2020 to all 28 UK neuroscience centres that have the potential capability to perform MT. Results Responses were received from 27/28 MT-capable centres (96%). Three of the 27 centres do not currently provide MT services. There was a 27.7% reduction in MTs performed during April 2020 compared with the first 3 months of the year. All MT patients in 20/24 centres that responded were considered as COVID-19 suspicious/positive unless or until proven otherwise. Twenty-two of the 24 centres reported delays to the patient pathway. Seventeen of the 24 centres reported that the COVID-19 pandemic had reduced training opportunities for specialist registrars (SpR). Fourteen of the 24 centres reported that the pandemic had hampered their development plans for their local or regional MT service. Conclusion The present survey has highlighted a trend of decreasing cases and delays in the patient pathway during the early stages of the COVID-19 pandemic across UK centres.

treatment for Acute Ischaemic Strokes (AIS) due to large vessel occlusion and significantly reduces morbidity and mortality.

We herein describe evolving practices in provision of MT services across the UK during the pandemic, the responses of and impact on MT teams, and the effects on training. We share the lessons learned.

The UK Neurointerventional Group (UKNG) and the British Society of Neuroradiologists (BSNR) sent out a national survey on 1 st May 2020 to all 28 UK Neuroscience Centres that have the potential capability to perform MT.

We received responses from 27/28 MT capable centres (96%). 3/27 centres do not currently provide MT services. 27.7% reduction in MTs performed during April 2020 compared with the first three months of the year. 20/24 centres that responded considered all MT patients as COVID-19 suspicious/positive unless or until proven otherwise. 22/24 centres reported delays to the patient pathway.

17/24 centres reported that the COVID-19 pandemic had reduced training opportunities for specialist registrars (SpR). 14/24 centres reported that the pandemic had hampered their development plans for their local or regional MT service.

Our survey has highlighted a trend of decreasing cases and delays in the patient pathway during the early stages of the COVID-19 pandemic across UK centres. In other respiratory tract infections, it is well documented that the risk of stroke is increased by a factor of 2.3 to 7.82 within the first 3 days of infection [1] . Although early evidence suggests COVID-19 also confers an increased risk of acute ischaemic stroke (AIS), the underlying pathological mechanism remains uncertain, although multiple reports suggest infected patients can develop a hypercoagulable condition [2] [3] [4] ; D-dimer levels are reported to be up to 12-fold higher than normal [2] .

In a study of 221 consecutive patients admitted to one hospital in Wuhan, China, with confirmed COVID-19, AIS occurred in 11 (5%) of patients with a range of stroke subtypes [2] . COVID-19 causes the most severe illness in the elderly, the immunocompromised, and those with other significant comorbidities [5, 6] ; most patients with COVID-19-related AIS fall into one or more of these categories. theatres have had to be significantly modified to protect both staff and patients.

National and international interventional and neuro-interventional societies have issued guidelines regarding recommended changes in practice, some of which have contributed to forming a framework for current clinical practice [8] , [9] . As the UK emerges from the worst of the initial peak of the pandemic, the authors, on behalf of the British Society of Neuroradiologists (BSNR) and the UK Neurointerventional Group (UKNG), sought to review the initial challenges to the UK's MT service and its response in order to evaluate and disseminate the lessons learned.

An online survey (Google Forms) was sent out on 1 May 2020 to all 28 UK neuroscience centres that have the potential capability to perform MT (Electronic Supplementary Material S1: Survey).

Standard data and statistical analysis (t-test and Fisher's exact test) was carried out using GraphPad Prism (GraphPad Software). Statistical significance was set at p<0.05.

To gain insight into MT service provision across the UK, the survey asked for the number of patients undergoing MT during each month from January to April 2020, in order to document the rate of MT procedures carried out immediately before and during the first 3 months of the COVID-19 pandemic in the UK. Fourteen of the 24 centres reported that the pandemic had hampered their development plans for their local or regional MT service.

Early evidence from Chinese studies demonstrated that COVID-19 can cause neurological deficits in infected patients and AIS in approximately 5% [4] [2] . Despite the Chinese data indicating high stroke incidence in COVID-19 patients, reports from most countries affected by the pandemic suggest that referrals to hospital for stroke treatment including MT actually fell, at least initially, following government-imposed lockdown measures. In a prospective study of 1,513 patients at 32 centres in all the administrative regions of France, there was a 21% decrease in MT case volumes during the initial stages of the COVID-19 epidemic [10] . Although some cities, notably New York, noticed a surge in MT numbers, including for AIS in younger patients [11] , a national survey of 856 hospitals across the USA found a 39% decline in the number of patients receiving stroke imaging [12] . The present survey indicates a similar trend with a 27.7% reduction in MTs performed in April 2020 across the UK.

The efficacy of MT is inversely proportional to the delay between stroke onset and LVO recanalisation. There are anecdotal accounts of patients being reluctant to present to hospital during the pandemic. Once admitted, additional safety measures were, of necessity, imposed onto the patient journey including added precautions on the stroke ward, in the CT machines, during ambulance transfer, during airway preparation, within the angiography suite, and during warding and repatriation. In France, significantly increased delays were found between imaging and groin puncture, overall and in transferred patients in particular [10] . The majority of the UK centres encountered delays to multiple steps in the patient pathway. Given the uncertainty over the duration of the pandemic, these issues need to be urgently addressed to ensure the best possible functional outcomes for patients [13] .

One of the challenges in identifying COVID-19 in AIS is an inability to obtain an accurate history of clinical symptoms due to underlying speech problems and/or confusion. Furthermore, at present COVID-19 status cannot be confirmed or excluded using antigen or antibody testing within the timeframe required for initial evaluation and decision-making regarding time-critical therapies for patients with AIS. A significant rate of false-negative antigen tests is known to occur. The Society of NeuroInterventional Surgery (SNIS) recommendation was that, for MT patients without a documented "negative" COVID-19 status, healthcare staff in the angiography room should wear enhanced PPE at all times, including N-95 or FFP2/FFP3 air-filtration mask [9] . Discordant pre-MT screening practices and variable use of PPE across the country was likely a reflection of initially confusing and rapidly changing guidelines at local, regional, and national level.

Given that the majority of patients presenting for MT will have unknown COVID-19 status, the Society for Neuroscience in Anesthesiology & Critical Care (SNACC),

strongly recommended a lower threshold for intubation, especially if the anaesthetist or INR have any concerns for possible conversion from LA to GA [8] , [9] , [14] . It is further recommended that intubation should not take place within the angiography suite, but rather in a negative-pressure environment, regardless of its location, prior to transfer to the angiography suite. In other respiratory tract infections, it is well documented that the risk of stroke is increased 8 by a factor of 2.3 to 7.82 within the first three days of infection [1] . Whilst early evidence 9

suggests COVID-19 also confers an increased risk of AIS, the underlying pathological 10 mechanism remains uncertain, although multiple reports suggest infected patients can 11 develop a hypercoagulable condition [2]- [4] ; D-dimer levels are reported to be up to 12-fold 12 higher than normal [2] . 13 14 In a study of 221 consecutive patients admitted to one hospital in Wuhan, China, with 15 confirmed COVID-19, acute ischaemic stroke (AIS) occurred in 11 (5%) of patients with a 16 range of stroke subtypes [2] . COVID-19 causes the most severe illness in the elderly, the 17 immunocompromised, and those with other significant comorbidities [5] , [6] ; most patients 18 with COVID-19 related AIS fall into one or more of these categories. for current clinical practice [8] , [9] . As the UK emerges from the worst of the initial peak of 30 the pandemic, the authors, on behalf of the British Society of Neuroradiologists (BSNR) and 31 the UK Neurointerventional Group (UKNG), sought to review the initial challenges to the 32 UK's MT service and its' response in order to evaluate and disseminate the lessons learned. 

Laboratory-confirmed respiratory infections as triggers for acute myocardial infarction and stroke: a self-controlled case series analysis of national linked datasets from Scotland

Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China

Severe acute respiratory syndrome coronavirus 2 infection and ischemic stroke

Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China

Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan

Characteristics and outcomes of 21 critically ill patients with COVID-19 in Washington State

Mechanical thrombectomy in acute ischemic stroke: Consensus statement by ESO-Karolinska Stroke Update

Minimally Invasive Neurological Therapy (ESMINT) recommendations for optimal interventional neurovascular management in the COVID-19 era

Society of NeuroInterventional Surgery recommendations for the care of emergent neurointerventional patients in the setting of COVID-19

Mechanical thrombectomy for acute ischemic stroke amid the COVID-19 outbreak: decreased activity, and increased care delays

large-vessel stroke as a presenting feature of covid-19 in the young

Collateral effect of covid-19 on stroke evaluation in the united states

Time to treatment with endovascular thrombectomy and outcomes from ischemic stroke: a meta-analysis

Anesthetic Management of Endovascular Treatment of Acute Ischemic Stroke During COVID-19 Pandemic

European Society of Minimally Invasive Neurological Therapy (ESMINT) and American Association of Neurological Surgeons (AANS) and Congress of Neurological Surgeons (CNS) Cerebrovascular Section

Neurointervention for emergent large vessel occlusion during the COVID-19 pandemic

A survey of preprocedural intubation practices for endovascular treatment of acute ischemic stroke

Figure 2. COVID-19 pre-MT acceptance screening procedures

Figure 3. Number of MTs performed under GA (Fisher's exact test)

Successful recanalisation defined as TICI 2B/2C/3 (Fisher's exact test)

can improve the management of MT-eligible patients during this or any future pandemic

Laboratory-confirmed respiratory infections as triggers for acute myocardial 288 infarction and stroke: a self-controlled case series analysis of national linked datasets 289 from Scotland

Prevalence and impact of cardiovascular metabolic diseases on COVID-19

Severe Acute 295

Respiratory Syndrome Coronavirus 2 Infection and Ischemic Stroke

STROKEAHA120030153

Neurologic Manifestations of Hospitalized Patients With Coronavirus 298 Disease

Clinical characteristics of 140 patients infected with SARS-CoV-2 in 301

Characteristics and Outcomes of 21 Critically Ill Patients With 303

Mechanical thrombectomy in acute ischemic stroke: Consensus 305 statement by ESO-Karolinska Stroke Update

Minimally Invasive Neurological Therapy (ESMINT) recommendations for optimal 309 interventional neurovascular management in the COVID-19 era

Society of NeuroInterventional Surgery recommendations for the 313 care of emergent neurointerventional patients in the setting of COVID-19

Mechanical Thrombectomy for Acute Ischemic Stroke Amid the 317

COVID-19 Outbreak: Decreased Activity, and Increased Care Delays

STROKEAHA120030373

Large-Vessel Stroke as a Presenting Feature of Covid-19 in the 320

Collateral Effect of Covid-323 19 on Stroke Evaluation in the United States

Time to treatment with endovascular thrombectomy and outcomes 326 from ischemic stroke: Ameta-analysis

Anesthetic Management of Endovascular Treatment of Acute 329

Ischemic Stroke During COVID-19 Pandemic: Consensus Statement from Society for 330

ward, in the CT scanners, during ambulance transfer, during airway preparation, within the 209 angiography suite, and during warding and repatriation. In France, significantly increased 210 delays were found between imaging and groin puncture, overall and in transferred patients 211 in particular [10] . We found that a majority of UK centres have encountered delays to 212 multiple steps in the patient pathway. Given the uncertainty over the duration of the 213 pandemic, these issues need to be urgently addressed to ensure the best possible functional 214 outcomes for patients [13] . 215 216 One of the challenges in identifying COVID-19 in AIS is an inability to obtain an accurate 217 history of clinical symptoms due to underlying speech problems and/or confusion. 218 Furthermore, at present COVID-19 status cannot be confirmed or excluded using antigen or 219 antibody testing within the time frame required for initial evaluation and decision-making 220 regarding time-critical therapies for patients with AIS. A significant rate of false negative 221 antigen tests is known to occur. The Society of NeuroInterventional Surgery (SNIS) 222 recommendation was that, for MT patients without a documented "negative" COVID-19 223 status, healthcare staff in the angiography room should wear enhanced PPE at all times, 224 including N-95 or FFP2/FFP3 air-filtration mask [9] . We postulate that discordant pre-MT 225 screening practices and variable use of PPE across the country was likely a reflection of 226 initially confusing and rapidly changing guidelines at local, regional and national level. possible conversion from LA to GA [8] , [9] , [14] . It is further recommended that intubation 233should not take place within the angiography suite, but rather in a negative pressure 234 environment, regardless of its location, prior to transfer to the angiography suite. Philip White -Study concepts and design, and manuscript editing.Robert Crossley -Study concepts and design, and manuscript editing.Wazim Izzath -Guarantor of integrity of the entire study, data analysis, Study concepts and design, statistical analysis, manuscript preparation, and manuscript editing.Not applicable -Clinical studies or experimental studies.

☒ The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.☐ The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: